The role of copper and magnesium in the pathogenesis and treatment of affective disorders;Udział miedzi i magnezu w patogenezie i terapii zaburzeń afektywnych

Psychiatria Polska

Volumn 39, Issue 5, 2005, Pages 911-920

  Siwek, Marcin ^a,c   Wróbel, Andrzej ^a   Dudek, Dominika ^a   Nowak, Gabriel ^b   Ziȩba, Andrzej ^a  

^a Uniwersytetu Medycznego   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Copper; Depression; Magnesium; NMDA receptor

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; AMPA RECEPTOR; CATECHOLAMINE; CLONAZEPAM; COPPER; DIZOCILPINE; DOPAMINE; GLUTAMINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN; PLACEBO; TRANQUILIZER;

ANTIDEPRESSANT ACTIVITY; CONFERENCE PAPER; COPPER BLOOD LEVEL; COPPER METABOLISM; DEPRESSION; DRUG MECHANISM; EXPERIMENTAL MODEL; HOMEOSTASIS; HUMAN; MAGNESIUM BLOOD LEVEL; MAGNESIUM DEFICIENCY; MAGNESIUM METABOLISM; MENTAL DISEASE; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REGULATORY MECHANISM; SYMPTOM; TRANQUILIZING ACTIVITY;

ANIMALS; ANTIDEPRESSIVE AGENTS; CEREBRAL CORTEX; COPPER; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; MAGNESIUM; MOOD DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 28544433263     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role of mono amines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996; 29: 2-11.
2. Sapru MK, Rao BS, Channabasavanna SM. Serum dopamine-beta-hydroxylase activity in clinical subtypes of depression. Acta Psychiatr. Scand. 1989; 80(5): 474-478.
3. Puzynski S, Rode A, Zaluska M. Studies on biogenic amine metabolizing enzymes (DBH, COMT, MAO) and pathogenesis of affective illness. I. Plasma dopamine-beta-hydroxylase activity in endogenous depression. Acta Psychiatr. Scand. 1983; 67(2): 89-95.
4. Solomons NW. Physiological interactions of minerals. W: Bodwell CE, Erdman JW Jr, red. Nutrient interactions. New York: Marcel Decker; 1988, s. 115-148.
5. Rathbun JK. Neuropsychological aspects of Wilson's disease. Int. J. Neurosc. 1996; 85: 221-229.
6. Tatoń J. Zaburzenia przemiany niektórych metali. W: Wojtczak A, red. Choroby wewnȩtrzne. Warszawa: PZWL; 1995, s. 171-180.
7. Akil M, Brewer GJ. Psychiatric and behavioral abnormalities in Wilson's disease. Adv. Neurol. 1995; 65: 171-178.
8. Keller R, Torta R, Lagget M, Crasto S, Bergamasco B. Psychiatric symptoms as late onset of Wilson's disease: neuroradiological findings, clinical features and treatment. Ital. J. Neurol. Sci. 1999; 20(1): 49-54.
9. Manser WW, Khan MA, Hazan KZ. Trace elements studies on Karachi population. Part IV: Blood copper, zinc, magnesium and lead levels in psychiatric patients with depression, mental retardation and seizure disorders. J. Pakistan Med. Assoc. 1989; 39: 269-274.
10. Narang RL, Gupta KR., Narang AP, Singh R. Levels of cooper and zinc in depression. Ind. J. Physiol. Pharmacol. 1991; 35: 272-274.
11. Schlegel-Zawadzka M, Zicba A, Dudek D, Krosńiak M, Szymaczek M, Nowak G. Serum trace elements in animal models and human depression. Part II. Copper. Hum. Psychopharmacol. Clin. Exp. 1999; 14: 447-451.
12. Maes M, Scharpe S, van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, Suy E. Higher a lantitripsin, haptoglobin, coeruloplasmin, and lower retinal binding protein plasma levels during depression: Further evidence for existence of an inflammatory response during that illness. J. Affect. Disord. 1992; 24: 183-192.
13. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Progr. Psychopharmacol. Biol. Psychiatry 1995; 19: 11-38.
14. Schlegel-Zawadzka M, Krośniak M, Nowak G. Brain copper levels after antidepressant treatment. W: Collery Ph, Bratter P, Negretti de Bratter V, Khassanova L, Etienne JC, red. Metal ions in biology and medicine, vol. 5. Paris: John Libbey; Eurotext 1998, s. 703-706.
15. Doreulee N, Yanovsky Y, Haas HL. Suppression of long-term potentiation in hippocampal slices by copper. Hippocampus 1997; 7(6): 666-669.
16. Trombley PQ, Shepherd GM. Differential modulation by zinc and copper of amino acid receptors from rat olfactory bulb neurons. J. Neurophysiol. 1996; 76(4): 2536-2546.
17. Vlachova V, Zemkova H, Vyklicky L Jr. Copper modulation of NMDA responses in mouse and rat cultured hippocampal neurons. Eur. J. Neurosci. 1996; 8(11): 2257-2264.
18. Hashizume N, Mori M. An analysis of hypermagnesemia and hypomagnesemia. Jap. J. Med. 1990; 29: 368-372.
19. Ziȩba A, Kata R, Dudek D, Schlegel Zawadzka M, Nowak G. Serum trace elements in animal models and human depression: part III. Magnesium. Relationship with copper. Hum. Psychopharmacol. Clin. Exp. 2000; 15: 631-635.
20. Oberleas D, Caldwell DF. Trace minerals in pregnancy. Int. J. Environ. Styd. 1981; 17: 85-98.
21. Murck H. Magnesium and affective disorders. Nutrit. Neurosc. 2002; 5(6): 375-389.
22. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J. Clin. Endocrinol. Metabol. 1962; 22: 1187-1192.
23. Whyte KF, Addis GJ, Whitesmith R, Reid JL. Adrenergic control of plasma magnesium in man. Clin. Sc. 1987; 72: 135-138.
24. Frizel D, Coppen A, Mark V. Plasma magnesium and calcium in depression. Brit. J. Psychiatry 1969; 115: 1375-1377.
25. Bjorum N. Electrolytes in blood in endogenous depression. Acta Psychiatr. Scand. 1972; 48: 59-68.
26. Widmer J, Bovier P, Karege F, Raffin Y, Hilleret H, Gaillard JM, Tissot R. Evolution of blood magnesium, sodium and potassium in depressed patients followed for three months. Neuropsychobiol. 1992. 26: 173-179.
27. Widmer J, Henrotte JG, Raffin Y, Bovier P, Hilleret H, Gaillard JM. Relationship between erythrocyte magnesium, plasma electrolytes and cortisol and intensity of symptoms in major depressed patients. J. Affect. Disord. 1995; 34: 201-209.
28. Linder J, Brismar K, Beck-Friis J, Saaf J, Wetterberg L. Calcium and magnesium concentrations in affective disorder: difference between plasma and serum in relation to symptoms. Acta Psychiatr. Scand. 1989; 80: 527 537.
29. Young LT, Robb JC, Levitt AJ, Cooke RG, Joffe RT. Serum Mg2 and Ca2/Mg2 ratio in major depressive disorder. Neuropsychobiol. 1996; 34: 26-28.
30. Pavlinac D, Langer R, Lenhard L, Dettos L. Magnesium in affective disorders. Biol. Psychiatry 1979; 14: 657-661.
31. Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S. Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. Psychiatry Res. 1999; 89(3): 239-246.
32. Chouinard G, Beauclair L, Geiser R, Etienne P. A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. Progr. Neuropsychopharmacol. Biol. Psychiatry 1990; 14(2): 171-180.
33. Giannini AJ, Nakoneczie AM, Melemis SM, Ventresco J, Condon M. Magnesium oxide augmentation of verapamil maintenance therapy in mania. Psychiatry Res. 2000; 93(1): 83-87.
34. Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991; 337(8744): 757-760.
35. Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. Obstet. Gynecol. 1991; 78(2): 177-181.
36. Decollogne S, Tomas A, Lecerf C, Adamowicz E, Seman M. NMDA receptor complex blockade by oral administration of magnesium: comparison with MK-801. Pharmacol. Biochem. Behav. 1997; 58: 261-268.
37. Poleszak E, Szewczyk B, Kȩdzierska E, Wlaź P, Pile A, Nowak G. Antidepressant-and anxiolytic-like activity of magnesium in mice. Pharmacol. Biochem. Behav. 2004 [w druku].
38. Danysz W, Zaja̧czkowski W, Parsons C. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 1995; 6: 455-474.
39. Nowak L, Bregestovski P, Acher P, Herbert A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurons. Nature 1984; 307: 462-465.
40. Grunze H, Walden J. Reduction of the frequency of occurrence of low magnesium induced field potentials in the hippocampus slice preparation of guinea pigs: a good screening tool for calcium antagonistic effects of anticonvulsant and antipsychotic drugs. Magnes. Res. 1997; 10(2): 119-126.
41. Gutierrez R, Armand V, Schuchmann S, Heinemann U. Epileptiform activity induced by low Mg2+ in cultured rat hippocampal slices. Brain Res. 1999; 815(2): 294-303.
42. Sadock BJ, Sadock VA. Mood disorders. W: Sadock BJ, Sadock VA, red. Synopsis of psychiatry. London: Lippincott Williams & Wilkins; 2003, s. 534-591.
43. Schneiderman JH, Arnold D, Advani A. Different changes in spontaneous field potential oscillations precede epileptiform bursting in hippocampal slices perfused with penicillin or reduced magnesium. Brain Res. 1990; 533(2): 275-285.
44. Standley CA, Irtenkauf SM, Cotton DB. Anticonvulsant effects of magnesium sulfate in hippocampal-kindled rats. J. Biomed. Sc. 1995; 2(1): 57-62.
45. Hsu KS, Ho WC, Huang CC, Tsai JJ. Transient removal of extracellular Mg(2+) elicits persistent suppression of LTP at hippocampal CA1 synapses via PKC activation. J. Neurophysiol. 2000; 84: 1279-1288.
46. Wolf M, Cuatrecasas P, Sahyoun N. Interaction of protein kinase C with membranes is regulated by Ca+2, phorbol esters, and ATP. J. Biol. Chem. 1985; 260: 15718-15722.
47. Gundersen V, Danbolt NC, Ottersen OP, Storm-Mathisen J. Demonstration of glutamate/aspartate uptake activity in nerve endings by use of antibodies recognizing exogenous D-aspartate. Neurosc. 1993; 57: 97-111.
48. Robinson MB, Sinor JD, Dowd LA, Kerwin JF Jr. Subtypes of sodium-dependent high-affinity L-[3H]glutamate transport activity: pharmacologic specifity and regulation by sodium and potassium. J. Neurochem. 1993; 60: 167-179.
49. Abe K, Saito H. Involvement of Na-K pump in L-glutamate clearance by cultured rat cortical astrocytes. Biol. Pharmac. Bull. 2000; 23: 1051-1054.
50. Szelenberger W, Niemcewicz S, Skalski M. Bezsenność: aktualny stan wiedzy. W: Szelenberger W, red. Bezsenność. Warszawa: Fundacja Wspierania Rozwoju Kliniki Psychiatrycznej Akademii Medycznej w Warszawie; 2000, s. 7-64.
51. Campbell IG, Feinberg I. Noncompetitive NMDA channel blockade during waking intensely stimulates NREM delta. J. Pharmacol. Exper. Therap. 1996; 276: 737-742.
52. Chollet D, Franken P, Raffin Y, Malafosse A, Widmer J, Tafti M. Blood and brain magnesium in inbred mice and their correlation with sleep quality. Am. J. Physiol. Regul. Integr. Compar. Physiol. 2000; 279: 2173-2178.
53. Depoortere H, Francon D, Llopis J. Effects of a magnesium-deficient diet on sleep organization in rats. Neuropsychobiol. 1993; 27: 237-245.
54. 2 supplementation reverses age-related neuroendocrine and sleep EEG changes in humans. Pharmacopsychiatry 2002; 35: 135-143.
55. Karssen AM, Meijer OC, Lucassen PJ, de Lange EC, de Boer AG, De Kloet ER. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinol. 2001; 142: 2686-2694.
56. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacol. 2000; 23: 477-501.
57. Hamada H, Tsuruo T. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988; 48: 4926-4932.
58. Henthorn TK, Liu Y, Mahapatro M, Ng KY. Active transport offentanyl by the blood-brain barrier. J. Pharmacol. Exper. Ther. 1999; 289: 1084-1089.